Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Xolair ® (omalizumab) for the treatment of chronic idiopathic urticaria (CIU), a form of chronic hives. The new use is for people 12 years of age and older who remain symptomatic despite treatment with H 1-antihistamine therapy 5. Until now, H 1-antihistamines have been the only approved therapy for CIU, with about 50 percent of patients having an inadequate response 3.
CIU is diagnosed when hives occur without an identifiable cause, spontaneously present, and reoccur for more than six weeks 1,3. CIU can have burdensome symptoms including swelling, severe itch, pain, and discomfort that may last for many months and even years 1,2. Approximately 1.5 million people in the U.S. develop CIU at some stage in their life 3,4. Women are twice as likely as men to experience CIU and most develop symptoms between the ages of 20 and 40 3,6.
“Chronic idiopathic urticaria can be difficult to manage because its causes are unknown, and other approved medicines aren't effective enough for many patients,” said Sandra Horning, M.D., chief medical officer and head of Global Product Development. “We are pleased to have Xolair as a new option for people with this serious skin condition.”
Xolair is the first biologic medicine and first medicine approved by the FDA for CIU since non-sedating H 1-antihistamines. Xolair is approved for people 12 years and older with CIU who remain symptomatic despite treatment with H 1-antihistamine therapy 5. Xolair is not used to treat other forms of urticaria (hives) and is not for use in children less than 12 years of age. It is jointly developed by Genentech and Novartis Pharma AG and is co-promoted in the U.S. with Novartis Pharmaceuticals Corporation.“CIU can be a frustrating condition for patients,” said Mike Tringale, senior vice president at the Asthma and Allergy Foundation of America (AAFA). “This new use for Xolair gives hope to appropriate patients who can go for months or even years without getting satisfactory itch and hive reduction.”
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts